Drug Type Small molecule drug |
Synonyms 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine, Trifluoperazine, Trifluoperazine hydrochloride (JAN/USP) + [10] |
Target |
Action antagonists |
Mechanism DRDs antagonists(Dopamine receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (16 Apr 1959), |
Regulation- |
Molecular FormulaC21H26Cl2F3N3S |
InChIKeyBXDAOUXDMHXPDI-UHFFFAOYSA-N |
CAS Registry440-17-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00799 | Trifluoperazine Hydrochloride |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Depressive Disorder | China | 01 Jan 1995 | |
| Schizophrenia | China | 01 Jan 1995 | |
| Anxiety Disorders | United States | 16 Apr 1959 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenocarcinoma of Lung | Preclinical | United States | 15 Apr 2012 |
Phase 1/2 | 2 | vditegeoix = pbhgbhcrro ivyhrhhlrx (clpvsxrthv, nlpivyatkg - wizmlfvgme) View more | - | 14 Dec 2022 |





